MiRNA-Based Technologies in Cancer Therapy

Overview

Journal J Pers Med

Date 2023 Nov 25

PMID 38003902

Authors

Maria Pagoni

Claudia Cava

Diamantis C Sideris

Margaritis Avgeris

Vassilios Zoumpourlis

Ioannis Michalopoulos

Nikolaos Drakoulis

Affiliations

Soon will be listed here.

Abstract

The discovery of therapeutic miRNAs is one of the most exciting challenges for pharmaceutical companies. Since the first miRNA was discovered in 1993, our knowledge of miRNA biology has grown considerably. Many studies have demonstrated that miRNA expression is dysregulated in many diseases, making them appealing tools for novel therapeutic approaches. This review aims to discuss miRNA biogenesis and function, as well as highlight strategies for delivering miRNA agents, presenting viral, non-viral, and exosomic delivery as therapeutic approaches for different cancer types. We also consider the therapeutic role of microRNA-mediated drug repurposing in cancer therapy.

Citing Articles

Role of miRNAs in Apoptosis Pathways of Immune Cells in Systemic Lupus Erythematosus.

Azizan A, Farhadi E, Faezi S, Jamshidi A, Alikhani M, Mahmoudi M Immun Inflamm Dis. 2025; 13(2):e70124.

PMID: 39912562 PMC: 11800236. DOI: 10.1002/iid3.70124.

Review of microRNA detection workflows from liquid biopsy for disease diagnostics.

Naranbat D, Herdes E, Tapinos N, Tripathi A Expert Rev Mol Med. 2025; 27:e11.

PMID: 39911053 PMC: 11879380. DOI: 10.1017/erm.2025.2.

Perspectives in MicroRNA Therapeutics for Cystic Fibrosis.

Finotti A, Gambari R Noncoding RNA. 2025; 11(1.

PMID: 39846681 PMC: 11755495. DOI: 10.3390/ncrna11010003.

MicroRNA Gets a Mighty Award.

Li Y, Chen S, Rao H, Cui S, Chen G Adv Sci (Weinh). 2025; 12(7):e2414625.

PMID: 39836690 PMC: 11831481. DOI: 10.1002/advs.202414625.

Exploring miRNA profile associated with cisplatin resistance in ovarian cancer cells.

Alghamian Y, Soukkarieh C, Aljapawe A, Murad H Biochem Biophys Rep. 2025; 41():101906.

PMID: 39830525 PMC: 11741906. DOI: 10.1016/j.bbrep.2024.101906.

References

Borchert G, Lanier W, Davidson B . RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006; 13(12):1097-101. DOI: 10.1038/nsmb1167. View

Lennox K, Owczarzy R, Thomas D, Walder J, Behlke M . Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. Mol Ther Nucleic Acids. 2013; 2:e117. PMC: 3759741. DOI: 10.1038/mtna.2013.46. View

Shadid M, Badawi M, Abulrob A . Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert Opin Drug Metab Toxicol. 2021; 17(11):1281-1292. DOI: 10.1080/17425255.2021.1992382. View

Hobel S, Aigner A . Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013; 5(5):484-501. DOI: 10.1002/wnan.1228. View

Zhu H, Hu F, Wang R, Zhou X, Sze S, Liou L . Arabidopsis Argonaute10 specifically sequesters miR166/165 to regulate shoot apical meristem development. Cell. 2011; 145(2):242-56. PMC: 4124879. DOI: 10.1016/j.cell.2011.03.024. View

Gong H, Liu C, Liu D, Liang C . The role of small RNAs in human diseases: potential troublemaker and therapeutic tools. Med Res Rev. 2005; 25(3):361-81. PMC: 7168392. DOI: 10.1002/med.20023. View

Fromm B, Zhong X, Tarbier M, Friedlander M, Hackenberg M . The limits of human microRNA annotation have been met. RNA. 2022; 28(6):781-785. PMC: 9074900. DOI: 10.1261/rna.079098.122. View

Orom U, Nielsen F, Lund A . MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008; 30(4):460-71. DOI: 10.1016/j.molcel.2008.05.001. View

Bertoli G, Cava C, Castiglioni I . MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer. Int J Mol Sci. 2016; 17(3):421. PMC: 4813272. DOI: 10.3390/ijms17030421. View

10.

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

11.

Sewell K, Geary R, Baker B, Glover J, Mant T, Yu R . Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther. 2002; 303(3):1334-43. DOI: 10.1124/jpet.102.036749. View

12.

Orellana E, Abdelaal A, Rangasamy L, Tenneti S, Myoung S, Low P . Enhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin. Mol Ther Nucleic Acids. 2019; 16:505-518. PMC: 6506612. DOI: 10.1016/j.omtn.2019.04.003. View

13.

Sand M, Skrygan M, Georgas D, Arenz C, Gambichler T, Sand D . Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. Mol Carcinog. 2011; 51(11):916-22. DOI: 10.1002/mc.20861. View

14.

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

15.

Saiyed A, Vasavada A, Johar S . Recent trends in miRNA therapeutics and the application of plant miRNA for prevention and treatment of human diseases. Futur J Pharm Sci. 2022; 8(1):24. PMC: 8972743. DOI: 10.1186/s43094-022-00413-9. View

16.

Kumar S, Ashraf M, Kumar A, Bae Y . Therapeutic Potential of microRNA Against Th2-associated Immune Disorders. Curr Top Med Chem. 2021; 21(8):753-766. DOI: 10.2174/1568026621666210303150235. View

17.

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

18.

Reda El Sayed S, Cristante J, Guyon L, Denis J, Chabre O, Cherradi N . MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers (Basel). 2021; 13(11). PMC: 8198729. DOI: 10.3390/cancers13112680. View

19.

Xiao X, Huang X, Ye F, Chen B, Song C, Wen J . The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. Sci Rep. 2016; 6:21735. PMC: 4763192. DOI: 10.1038/srep21735. View

20.

Arghiani N, Shah K . Modulating microRNAs in cancer: Next-generation therapies. Cancer Biol Med. 2021; . PMC: 8958885. DOI: 10.20892/j.issn.2095-3941.2021.0294. View